Therapeutic approach in patients with concomitant disease/drug--drug interactions (roxatidine acetate).
Possible mechanisms of drug interactions with H2-antagonists are outlined. The mode of action of roxatidine acetate on hepatic microsomal enzymes is contrasted with those of cimetidine and ranitidine, and their differing structure-activity relationships are discussed. In the light of the mechanisms of drug interactions with H2-antagonists, clinical studies with roxatidine acetate are contrasted with published interaction data of cimetidine and ranitidine. The therapeutic consequences of these data are considered.
Collins
J D
JD
Clinical Pharmacology Dept., Hoechst UK Limited, Walton, Buckinghamshire, England.
D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D002927:Cimetidine / Q000627:therapeutic use; D004347:Drug Interactions; D006635:Histamine H2 Antagonists / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D010437:Peptic Ulcer / Q000188:drug therapy*; D010880:Piperidines / Q000627:therapeutic use*; D011899:Ranitidine / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D010880:Piperidines; D002927:Cimetidine; D011899:Ranitidine; C053742:roxatidine acetate